Navigation Links
ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
Date:9/9/2008

$38,282,000 $43,790,000

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable $4,186,000 $2,074,000

Other current liabilities 2,589,000 2,233,000

Total current liabilities 6,775,000 4,307,000

Long-term liabilities 982,000 1,671,000

Stockholders' equity 30,525,000 37,812,000

$38,282,000 $43,790,000

THERMOGENESIS CORP.

Condensed Consolidated Statements of Operations

(Unaudited)

Three Months Ended Years Ended

June 30, June 30,

2008 2007 2008 2007

Net revenues $7,182,000 $3,520,000 $21,946,000 $16,751,000

Cost of revenues 4,832,000 2,596,000 14,976,000 11,554,000

Gross profit 2,350,000 924,000 6,970,000 5,197,000

Expenses:

Selling, general

and

administrative 2,838,000 2,817,000 10,165,000 9,630,000

Research and

development 2,157,000 1,139,000 7,172,000 4,108,000

Total operating

expenses 4,995,000 3,956,000 17,337,000 13,738,000

Interest and other

income, net 161,000 419,000 1,186,000 1,765,000

Net loss ($2,484,000) ($2,613,000) ($9,181,000) ($6,776,000)

Basic and diluted

net loss per

common share ($0.04) ($0.05) ($0.16) ($0.12)

Shares used in

computing

per share data 55,956,452 55,369,291 55,754,578 55,169,977

THERMOGENESIS CORP.<
'/>"/>

SOURCE ThermoGenesis Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
2. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
3. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
4. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
5. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 2008
6. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
7. ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets
8. ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health
9. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
10. ThermoGenesis Announces Receipt of CE Mark for MarrowXpress(TM)
11. ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 2013   Oligomerix, Inc. , a privately ... therapeutics for Alzheimer,s disease (AD) and related neurodegenerative ... B financing, which includes both issuance of new ... approximately $2.8M in new investments in the Company.  ... raise. Funding from the Series ...
(Date:5/22/2013)... May 22, 2013  Cleveland BioLabs, Inc. (NASDAQ: CBLI) today ... Second Annual Marcum LLP Microcap Conference, May 30, in ... Neil Lyons , CPA, Chief Financial Officer of ... on May 30 at 1:30 p.m. Eastern Time.  A live ... on the Investors page of the Cleveland BioLabs website at ...
(Date:5/22/2013)... Chester, PA (PRWEB) May 22, 2013 ... company as Fermentation Manager. Mr. McErlean has an ... variety of leadership positions throughout his career. ... “We are very pleased to have Mike join our ... newly installed large scale fermentation and downstream ...
(Date:5/21/2013)... , May 21, 2013  On May 9, ... ), the global business advisory firm dedicated to ... (the "Company"), announced that it has combined the ... formerly included within the Corporate Finance/Restructuring segment with ... to form a single integrated practice whose financial ...
Breaking Biology Technology:Oligomerix, Inc. Completes Series B Financing 2Oligomerix, Inc. Completes Series B Financing 3Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference 2Envera Appoints Michael McErlean Fermentation Manager 2FTI Consulting Releases Realigned Segment Information Reflecting Newly Combined Health Solutions Practice 2
... TEL-AVIV, Israel and PORTLAND, Oregon, October 2 , ... Exertion Identified,Abnormalities of Cardiovascular Function and Might be Useful ... Treatment in,Clinical Practice and Trials , ... Exercise Cardiac,Output (ECO(R)) stress test protocol for chronic heart ...
... --Company to Host Conference Call-- , CALGARY, Oct. 2 ... announced that it has reached an agreement with the ... Protocol Assessment (SPA) process for the design of a ... and carboplatin in patients with platinum-refractory head and neck ...
... ... Situational Leadership V™ series to its portfolio. , ... San Francisco, Calif. (PRWEB) October 2, 2009 -- ... series specifically for biotech and specialty pharma companies. The new series includes Situational Leadership ...
Cached Biology Technology:New Multicenter Study Finds That Cardiac Function Measured During Stress Testing With Cheetah Medical's BIOREACTANCE(R) Noninvasive Technology Offers New Insights Into Heart Failure 2New Multicenter Study Finds That Cardiac Function Measured During Stress Testing With Cheetah Medical's BIOREACTANCE(R) Noninvasive Technology Offers New Insights Into Heart Failure 3Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 2Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 3Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 4Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers 5Perceptum Group Announces New Situational Leadership V Series 2
(Date:5/21/2013)... developed a new method for delivering molecules into ... cell surface. The technique could find applications in ... , Bulk electroporation a technique used to ... the cell membrane that are caused by exposing ... popular method of cell transfection. (Cell transfection is ...
(Date:5/21/2013)... of Michigan Water Center today awarded 12 research ... restoration and protection efforts. , The two-year grants ... including efforts to track the remediation of harmful ... control non-native weedy plant invasions; study chromosomal damage ... to restoration activities. , The grants were awarded ...
(Date:5/21/2013)... Researchers at the University of Illinois at Chicago College of ... and stores fat -- its main energy source -- and ... disease, under a new $2 million, 4-year grant from the ... heart changes how it uses fuel for energy. These changes ... disease and are different in men and women, says E. ...
Breaking Biology News(10 mins):Single-cell transfection tool enables added control for biological studies 2U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4Do men's and women's hearts burn fuel differently? 2
... Rising atmospheric carbon dioxide is largely responsible for recent global ... of scientists, including two Smithsonian ecologists, have found that this ... of its negative effects on one of the planet,s most ... Proceedings of the National Academy of Sciences the ...
... has identified several common genetic variants related to a ... early online release in the journal Nature Genetics ... newly discovered, that influence the QT interval measured on ... findings could eventually help to prevent sudden cardiac death ...
... Mammalian skin requires constant maintenance, but how do skin ... In the March 23, 2009 issue of the ... colleagues reveal that skin fibroblasts use a protein called ... too quickly. Their results highlight how communications between different ...
Cached Biology News:Scientists find climate change to have paradoxical effects in coastal wetlands 2Scientists find climate change to have paradoxical effects in coastal wetlands 3Common gene variants influence risk factor for sudden cardiac death 2Common gene variants influence risk factor for sudden cardiac death 3Time (and PPAR-beta/delta) heals all wounds 2Time (and PPAR-beta/delta) heals all wounds 3
100 g monoclonal antibody which can immunocapture ~10 g of Complex IV from heart mitochondria. Also included are 2 mg of bovine heart mitochondria for control immunocapture....
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Rabbit polyclonal to GPR56 ( Abpromise for all tested applications). entrezGeneID: 9289 SwissProtID: Q9Y653...
Annexin V Binding Buffer, 10X Concentrate Buffer , 50 ml Consult technical datasheet for details....
Biology Products: